Related Experiment Video
Updated: Aug 24, 2026

Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology
Published on: March 22, 2012
Management of invasive aspergillosis in high-risk patients
1Division of Nephrology and Hypertension, Oregon Health and Science University, Portland, USA.
Abstract:
Invasive aspergillosis can be difficult to diagnose and control, and conventional drug treatment is often highly toxic, producing medical complications that further compromise patients' health status and escalate health care costs. This article describes the clinical manifestations of Aspergillus infection and discusses approaches to its therapy, including newer pharmaceutical agents with fewer adverse effects, which offer the potential to improve outcomes and substantially lower the cost of treating aspergillosis.
Insights
Diagnosing and treating invasive aspergillosis is challenging. Newer therapies offer improved outcomes and reduced costs compared to traditional treatments, which often cause severe side effects.
Area of Science:
- Medical Mycology
- Infectious Diseases
- Clinical Pharmacology
Background:
- Invasive aspergillosis presents diagnostic and therapeutic challenges.
- Conventional treatments for Aspergillus infections are often toxic, leading to complications and increased healthcare costs.
Purpose of the Study:
- To review the clinical manifestations of Aspergillus infections.
- To discuss current and emerging therapeutic strategies for invasive aspergillosis.
Main Methods:
- Literature review of clinical presentations of Aspergillus infections.
- Analysis of therapeutic approaches, including novel pharmaceutical agents.
Main Results:
- Invasive aspergillosis requires careful diagnosis and management.
- Newer antifungal agents demonstrate potential for better efficacy and safety profiles.
Conclusions:
- Emerging therapies for invasive aspergillosis may improve patient outcomes.
- Optimized treatment strategies can potentially reduce the economic burden of aspergillosis.
Related Concept Videos
Cryptococcal Meningitis
Transmission-based Precautions II: Airborne and Protective Environment
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
Asthma-IV: Nursing Management
First, in...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
